Kahana Dialysis is a medicare approved dialysis facility center in Lahaina, Hawaii and it has 12 dialysis stations. It is located in Maui county at 10 Hoohui Road Suite 100, Lahaina, HI, 96761. You can reach out to the office of Kahana Dialysis at (808) 669-6628. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Kahana Dialysis has the following ownership type - Profit. It was first certified by medicare in January, 2006. The medicare id for this facility is 122515 and it accepts patients under medicare ESRD program.
| Name | Kahana Dialysis |
|---|---|
| Location | 10 Hoohui Road Suite 100, Lahaina, Hawaii |
| No. of Dialysis Stations | 12 |
| Medicare ID | 122515 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 10 Hoohui Road Suite 100, Lahaina, Hawaii, 96761 | |
| (808) 669-6628 | |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
| NPI Number | 1487037206 |
| Doing Business As | Liberty Dialysis Hawaii Llc |
| Address | 10 Hoohui Rd Ste 100 Lahaina, Hawaii, 96761 |
| Phone Number | (808) 669-6628 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 28 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 7 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 44 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 439 |
| Percentage of adult patients getting regular hemodialysis at the center | 100 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Kahana Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 50 |
| Hypercalcemia patient months | 486 |
| Patients with Serumphosphor | 53 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 34 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 26 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 116 |
| Patient months included in arterial venous fistula and catheter summaries | 450 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 72 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 2 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 39 |
| Hospitalization Rate in facility | 134.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 271.8 |
| Hospitalization Rate: Lower Confidence Limit | 69.9 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Kahana Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 23.6 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 42 |
| Readmission Rate: Lower Confidence Limit | 10.7 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Kahana Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.95 (As Expected) |
| SIR: Upper Confidence Limit | 4.31 |
| SIR: Lower Confidence Limit | .71 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Kahana Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 38 |
| Transfusion Rate in facility | 22.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 95.9 |
| Transfusion Rate: Lower Confidence Limit | 6.4 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Kahana Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 201 |
| Mortality Rate in facility | 7.8 (Better than Expected) |
| Mortality Rate: Upper Confidence Limit | 13.6 |
| Mortality Rate: Lower Confidence Limit | 4 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago
Rainbow Dialysis Lahaina Location: 305 Keawe Street Suite 503, Lahaina, Hawaii, 96761 Phone: (808) 661-8372 |
News Archive
Halfway through the six-month enrollment period for private insurance under the health care law, just one in four adult enrollees are between ages 18 and 34, the crucial demographic group whose participation rates are key to keeping monthly premiums affordable.
Allergic reactions in the skin can be caused by many different chemical compounds found in creams, cosmetics, and other topical consumer products, but how they trigger the reaction has remained somewhat mysterious.
Networking Technology, Inc., the leader in electronic healthcare technology, today announced that their standalone eprescribing software product received Gold Solution Provider status from Surescripts. NTI's standalone ePrescribing solution RxNT eRx has achieved Gold Solution Provider status placing their standalone eprescribing solution into an elite group of certified products for the fourth year in a row.
Respicardia, a developer of implantable therapies to improve respiratory and cardiovascular health, announced results from the remede System Pilot Study during the Heart Failure Society of America Late Breaking Scientific Session in Orlando. Dr. William T. Abraham of The Ohio State University Wexner Medical Center in Columbus presented the results for the first and only implantable device for respiratory rhythm management to treat central sleep apnea.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
› Verified 3 days ago